ADAMTS12 is a secreted metalloprotease that functions as a multifaceted regulator of extracellular matrix remodeling with context-dependent pathological roles. Primary function involves ECM degradation through proteolytic cleavage of substrates including hemicentin 1, COMP, aggrecan, and alpha-2 macroglobulin 12. Mechanistically, ADAMTS12 restructures ECM composition to enable activation and migration of injury-responsive fibroblasts characterized by elevated JAK/STAT signaling 1, while modulating cell-matrix interactions that influence adhesion and migration 3. Disease relevance is complex and context-dependent. In fibrosis, ADAMTS12 is strongly upregulated during active fibrogenesis in heart and kidney, with knockout studies confirming its critical role in fibroblast-mediated pathogenesis 1. In cancer, ADAMTS12 promotes oncogenic properties including migration, epithelial-mesenchymal transition, and angiogenesis across pancreatic, head-and-neck, and gastric cancers, associating with poor prognosis 456. In osteoarthritis, ADAMTS12 participates in cartilage ECM degradation; its expression is regulated by the METTL3/IGF2BP2/STAT1 axis and correlates with disease progression 72. Notably, serum ADAMTS12 levels are significantly reduced in Type 2 diabetics but show no association with diabetic complications 8. Clinical significance centers on ADAMTS12 as a prognostic biomarker and therapeutic target in fibrotic and malignant diseases, with pathway-specific targeting opportunities including JAK/STAT, PI3K/Akt, and MAPK/VEGF axes.